Emily Karanges

Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes.

Emily A Karanges, Natasha Ting, Lisa Parker, Alice Fabbri, Lisa Bero

Journal article  |  2020  |  Australian Journal of General Practice

BACKGROUND AND OBJECTIVES: Pharmaceutical industry interactions with professional medical associations have come under scrutiny, y..

Policies affecting the supply and access of opioid analgesics: a scoping review protocol.

Kellia Chiu, Sally McDonald, Tess Legg, Emily A Karanges, Lisa Bero

Journal article  |  2019  |  JBI Evidence Synthesis

OBJECTIVE: This scoping review aims to describe and map the range of evaluated policies that affect the supply and access of opioi..

Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study.

Behrad Behdarvand, Emily A Karanges, Lisa Bero

Journal article  |  2019  |  BMJ Open

OBJECTIVES: To describe the nature, frequency and content of non-vitamin K oral anticoagulant (NOAC)-related events for healthcare..

Understanding the Nature and Extent of Pharmaceutical Industry Payments to Nonphysician Clinicians.

Emily A Karanges, Quinn Grundy, Lisa Bero

Journal article  |  2019  |  JAMA Internal Medicine

Trends in self-poisoning and psychotropic drug use in people aged 5-19 years: a population-based retrospective cohort study in Australia

Rose Cairns, Emily A Karanges, Anselm Wong, Jared A Brown, Jeff Robinson, Sallie-Anne Pearson, Andrew H Dawson, Nicholas A Buckley

Journal article  |  2019  |  BMJ Open

Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.

Lisa Parker, Emily A Karanges, Lisa Bero

Journal article  |  2019  |  BMJ Open

OBJECTIVES: To describe and quantify disclosed payments from the pharmaceutical industry to the healthcare sector, and to examine ..

Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study

Andrea L Schaffer, Emily A Karanges, Nicholas A Buckley, Andrew Wilson, Louisa Degenhardt, Briony Larance, Sallie-Anne Pearson

Journal article  |  2019  |  Pharmacoepidemiology and Drug Safety

PURPOSE: Despite increasing use of oxycodone/naloxone controlled-release (CR) in Australia, little is known about how it has affec..

Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey.

Emily A Karanges, Anastasia Suraev, Natalie Elias, Ramesh Manocha, Iain S McGregor

Journal article  |  2018  |  BMJ Open

OBJECTIVES: To examine the knowledge and attitudes of Australian general practitioners (GP) towards medicinal cannabis, including ..

Prescription Opioid Access Patterns and Factors Associated with Increasing Number of Prescribers, Pharmacies, and Dispensings: An Observational Study Using Pharmaceutical Claims

Bianca Blanch, Louisa Degenhardt, Nicholas A Buckley, Natasa Gisev, Timothy Dobbins, Emily A Karanges, Briony Larance, Sarah Larney, Sallie-Anne Pearson

Journal article  |  2018  |  Pain Medicine

Trends in opioid utilisation in Australia, 2006-2015: Insights from multiple metrics

Emily A Karanges, Nicholas A Buckley, Jonathan Brett, Bianca Blanch, Melisa Litchfield, Louisa Degenhardt, Sallie-Anne Pearson

Journal article  |  2018  |  Pharmacoepidemiology and Drug Safety

To what extent do data from pharmaceutical claims underestimate opioid analgesic utilisation in Australia?

Natasa Gisev, Sallie-Anne Pearson, Emily A Karanges, Briony Larance, Nicholas A Buckley, Sarah Larney, Timothy Dobbins, Bianca Blanch, Louisa Degenhardt

Journal article  |  2018  |  Pharmacoepidemiology and Drug Safety

Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study.

Jonathan Brett, Benjamin Daniels, Emily A Karanges, Nicholas A Buckley, Carl Schneider, Atheer Nassir, Andrew J McLachlan, Sallie-Anne Pearson

Journal article  |  2017  |  British Journal of Clinical Pharmacology

AIMS: To describe psychotropic polypharmacy in Australia between 2006 and 2015. METHODS: We used pharmaceutical claims from a nati..

Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure.

Jonathan Brett, Emily A Karanges, Benjamin Daniels, Nicholas A Buckley, Carl Schneider, Atheer Nassir, Helga Zoega, Andrew J McLachlan, Sallie-Anne Pearson

Journal article  |  2017  |  Australian & New Zealand Journal of Psychiatry

OBJECTIVE: To examine changes in annual patterns of psychotropic medication use in Australia from 2007 to 2015. METHODS: We used a..

Benchmarking prescription drug access patterns in pharmaceutical claims: a method for identifying high and potentially harmful opioid use in Australia and Canada?

Bianca Blanch, Emilie Gladstone, Kate Smolina, Nicholas A Buckley, Emily A Karanges, Steven G Morgan, Sallie-Anne Pearson

Journal article  |  2017  |  Journal of Pharmaceutical Health Services Research

Too much or not enough? A comment on discrepancies in published estimates of opioid use in Australia.

EA Karanges, S-A Pearson

Journal article  |  2016  |  Internal Medicine Journal

Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims.

Emily A Karanges, Bianca Blanch, Nicholas A Buckley, Sallie-Anne Pearson

Journal article  |  2016  |  British Journal of Clinical Pharmacology

AIM: The aim of this paper is to investigate 25-year trends in community use of prescribed opioid analgesics in Australia, and to ..

Contrasting regional Fos expression in adolescent and young adult rats following acute administration of the antidepressant paroxetine.

Emily A Karanges, Linnet Ramos, Bruno Dampney, Anastasia S Suraev, Kong M Li, Iain S McGregor, Glenn E Hunt

Journal article  |  2016  |  Brain Research Bulletin

Adolescents and adults may respond differently to antidepressants, with poorer efficacy and greater probability of adverse effects..

The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers.

Leigh Mellish, Emily A Karanges, Melisa J Litchfield, Andrea L Schaffer, Bianca Blanch, Benjamin J Daniels, Alicia Segrave, Sallie-Anne Pearson

Journal article  |  2015  |  BMC Research Notes

BACKGROUND: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. This paper provides a practical..

Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009-2012: focus on children, adolescents and prescriber specialty.

Emily A Karanges, Chris P Stephenson, Iain S McGregor

Journal article  |  2014  |  Australian & New Zealand Journal of Psychiatry

OBJECTIVE: Longitudinal trends in the dispensing of antidepressant, antipsychotic and ADHD medications from 2009-2012 were examine..

Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of "paradoxical" antidepressant responses in young persons.

Emily A Karanges, Mohammed A Kashem, Ranjana Sarker, Eakhlas U Ahmed, Selina Ahmed, Petra S Van Nieuwenhuijzen, Andrew H Kemp, Iain S McGregor

Journal article  |  2013  |  Frontiers in Pharmacology

Selective serotonin reuptake inhibitors (SSRIs) are commonly recognized as the pharmacological treatment of choice for patients wi..

Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011.

Chris P Stephenson, Emily Karanges, Iain S McGregor

Journal article  |  2013  |  Australian & New Zealand Journal of Psychiatry

OBJECTIVE: This study examined longitudinal trends in the dispensing of psychotropic medications in Australia from January 2000 to..

Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion.

Craig P Motbey, Emily Karanges, Kong M Li, Shane Wilkinson, Adam R Winstock, John Ramsay, Callum Hicks, Michael D Kendig, Naomi Wyatt, Paul D Callaghan, Iain S McGregor

Journal article  |  2012  |  PLoS ONE

Mephedrone (4-methylmethcathinone, MMC) is a popular recreational drug, yet its potential harms are yet to be fully established. T..

Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.

Charlotte Klein, Emily Karanges, Adena Spiro, Alexander Wong, Jarrah Spencer, Thanh Huynh, Nathan Gunasekaran, Tim Karl, Leonora E Long, Xu-Feng Huang, Kelly Liu, Jonathon C Arnold, Iain S McGregor

Journal article  |  2011  |  Psychopharmacology

RATIONALE: The interactions between Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) during chronic treatment, and at equival..

Antidepressants and adolescent brain development

E Karanges, IS McGregor

Journal article  |  2011  |  Future Neurology

Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents?

Emily Karanges, Kong M Li, Craig Motbey, Paul D Callaghan, Andrew Katsifis, Iain S McGregor

Journal article  |  2011  |  The International Journal of Neuropsychopharmacology

Selective serotonin reuptake inhibitor use is associated with increased risk of suicidal ideation in adolescent humans, yet the ne..